首页> 外文期刊>Experimental Animals >Development of a Protocol for Selection of GenesFit for the In Vivo Knockdown Method and its Application to Insulin Receptor Substrate Genesin Mice
【24h】

Development of a Protocol for Selection of GenesFit for the In Vivo Knockdown Method and its Application to Insulin Receptor Substrate Genesin Mice

机译:体内敲除方法的基因选择协议的发展及其在小鼠胰岛素受体底物基因中的应用

获取原文
       

摘要

Prediabetes model mice in which more than one gene associated with diabetes is knocked down simultaneously are potentially useful for pharmaceutical and medical studies of diabetes. However, the effective conditions for sufficient knockdown in vivo are dependent on the intrinsic properties of the target genes. It is necessary to investigate which genes are applicable or not to the in vivo knockdown method. In this study, insulin receptor substrate 1 and 2 ( Irs-1 , Irs-2 ) were selected as target genes. Effective siRNAs against the respective genes were designed, and their efficacy was confirmed by cell-based experiments. Based on the results of siRNAs, shRNA expression vectors against Irs-1 and Irs-2 were constructed, respectively. Their efficacy was also confirmed by cell-based experiments. A hydrodynamic method was applied to the delivery of the vectors to mice. This method was found to be effective for predominant delivery to the liver by demonstrative delivery of an EGFP expression vector and successive histochemical analysis. Fifty micrograms of the shRNA expression vector was injected into the tail vein. After 24 h, the liver, pancreas, and muscle were isolated, and the expression levels of Irs-1 and Irs-2 were analyzed by quantitative RT-PCR. In the liver, Irs-2 was effectively knocked down to 60% of the control level, but Irs-1 was not influenced even under the same conditions. The protocol developed here is feasible for the selection of genes fit for in vivo knockdown method.
机译:同时敲除一个以上与糖尿病有关的基因的糖尿病前期模型小鼠可能对糖尿病的药物和医学研究有用。但是,体内充分敲低的有效条件取决于靶基因的内在特性。有必要研究哪些基因适用于体内敲除方法。在这项研究中,选择胰岛素受体底物1和2(Irs-1,Irs-2)作为靶基因。设计了针对各个基因的有效siRNA,并通过基于细胞的实验证实了其有效性。基于siRNA的结果,分别构建了针对Irs-1和Irs-2的shRNA表达载体。通过基于细胞的实验也证实了它们的功效。将流体动力学方法应用于载体向小鼠的递送。通过示范性递送EGFP表达载体和连续的组织化学分析,发现该方法对于主要递送至肝脏是有效的。将五十微克shRNA表达载体注射到尾静脉中。 24小时后,分离肝脏,胰腺和肌肉,并通过定量RT-PCR分析Irs-1和Irs-2的表达水平。在肝脏中,有效降低Irs-2达到对照水平的60%,但是即使在相同条件下,Irs-1也不会受到影响。此处开发的协议可用于选择适合体内敲除法的基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号